Browsing by Subject "Resection"

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Healthcare Resource Use Associated With Tumor-Induced Osteomalacia: A Literature Review
    (Oxford University Press, 2024) Jan de Beur, Suzanne M.; Dahir, Kathryn M.; Imel, Erik A.; Zanchetta, María Belén; Williams, Angela; Li, Zhiyi; Webb, Neil; Crowe, Victoria; Johnson, Ben; Carpenter, Thomas O.; Medicine, School of Medicine
    Context: Tumor-induced osteomalacia (TIO) is an ultra-rare, paraneoplastic syndrome caused by tumors that secrete fibroblast growth factor 23 (FGF23). Initial signs and musculoskeletal symptoms can be nonspecific and unrecognized, leading to long delays in diagnosis and treatment, and resulting in severe and progressive disability in patients with TIO. Objective: This review aimed to identify published evidence on healthcare resource use in TIO to better understand the burden of the disease. Evidence acquisition: A targeted literature review was conducted to identify publications reporting on disease characteristics and healthcare resource use associated with TIO. Evidence synthesis: In total, 414 publications were included in the review, of which 376 were case reports. From the case reports, data on 621 patients were extracted. These patients had a mean (SD) age of 46.3 (15.8) years; 57.6% were male. Mean time from first symptoms to diagnosis of TIO was 4.6 (4.7) years and, in cases where imaging tests were reported, patients underwent a mean of 4.1 (2.7) procedures. Tumor resection was attempted in 81.0% of patients and successful in 67.0%. Fracture was reported in 49.3% of patients. Results from association analyses demonstrated that longer time to diagnosis was associated with poorer tumor resection outcomes and a higher probability of tumor recurrence. Unfavorable tumor resection outcomes were associated with greater use of pharmacologic treatment and a greater likelihood of orthopedic surgery. Conclusion: TIO is associated with a substantial healthcare resource burden. Improvements in the diagnostic process could lead to better management of TIO, thereby benefiting patients and reducing that burden.
  • Thumbnail Image
    Item
    Role for targeted resection in the multidisciplinary treatment of metastatic gastrointestinal stromal tumor
    (AME Publishing Company, 2019-04-29) Kim, Bradford J.; Milgrom, Daniel P.; Feizpour, Cyrus; Kays, Joshua K.; Koniaris, Leonidas G.; Surgery, School of Medicine
    The management of advanced gastrointestinal stromal tumors (GISTs) has evolved in the modern era due to the discovery of c-kit mutations and the development of tyrosine kinase inhibitors (TKIs). Until the advent of TKIs such as imatinib, the median survival reported for patients with advanced GIST was 19 months. Although surgery is the treatment of choice for resectable primary GIST, its role in cases of recurrence and metastasis remains to be unclear. This review outlines the potential beneficial role of repeat surgical resection in the multidisciplinary treatment of advanced GIST in the era of TKIs.